Výsledky vyhledávání - "Pawel J. Robak"

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1-3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Autor: Sosana Delimpasi, Meletios A. Dimopoulos, Jan Straub, Argiris Symeonidis, Roman Hájek, Cyrille Touzeau, Viralkumar K. Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey V. Matous, Pawel J. Robak, Kaveri Suryanarayan, Miguel Villareal, Dasha Cherepanov, Jaydeep K. Srimani, Huilan Yao, Richard Labotka, Robert Z. Orlowski

Publikováno v: Blood. 140:9995-9997

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::368da8e5a1eb1891530e35e672f38c44
https://doi.org/10.1182/blood-2022-163092

Zobrazit plný text záznamu

OCEAN (OP-103): Melflufen/Dexamethasone Compared with Pomalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-Age Subgroup Analysis of Older Patients

Autor: Maria-Victoria Mateos, Pawel J. Robak, Laura Rosiñol, Argiris Symeonidis, Pieter Sonneveld, Marcus Thuresson, Catriona Byrne, Johan Harmenberg, Roman Hájek

Publikováno v: Blood. 138:2741-2741

Background: Older patients (pts) with relapsed/refractory multiple myeloma (RRMM) represent a particularly difficult-to-treat population due to comorbidities, frailty or reduced fitness level, and treatment with concomitant medications (Larocca et al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::be52bf31172a6ba219930c9a8a6f3f1d
https://doi.org/10.1182/blood-2021-147005

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání